Lakefront Biotherapeutics (LKFT) Cash & Equivalents (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has 13 years of Cash & Equivalents data on file, last reported at $102.9 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $102.9 million, up 52.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $102.9 million (up 52.24% YoY), and the FY2025 annual result was $102.3 million, up 49.0% from the prior year.
• Cash & Equivalents climbed to $102.9 million in Q1 2026 per LKFT's latest filing, from $102.3 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $2.5 billion in Q1 2022 and troughed at $67.6 million in Q1 2025.
• A 5-year average of $505.9 million and a median of $179.6 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2026: Cash & Equivalents plunged 79.71% in 2022, then soared 52.24% in 2026.
• A 5-year view of Cash & Equivalents shows it stood at $518.4 million in 2022, then sank by 65.38% to $179.5 million in 2023, then slumped by 61.75% to $68.6 million in 2024, then jumped by 49.0% to $102.3 million in 2025, then increased by 0.58% to $102.9 million in 2026.
• Business Quant data shows LKFT's Cash & Equivalents at $102.9 million in Q1 2026, $102.3 million in Q4 2025, and $75.4 million in Q3 2025.